Phase 3 N=68 Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Biopsies — 2.46; 2.64; 2.56; 2.07 UI/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
Phase 2 N=175 Preventing Diabetic Foot Ulcers Through Cleaner Feet
Diabetic Foot Ulcer
Primary: Time to New Foot Complication Among All Randomized Participants — 12; 14 Participants
N/A N=8 ULCERS - Electrical Stimulation in Diabetic Foot Ulceration
Diabetes
Primary: Number of Day Until 50% Healing of Leg Ulcer — 55; 30 Days
Phase 2 N=30 Micro-mobile Foot Compression and Diabetic Foot
Diabetes · PAD · Lower Extremity Edema
Primary: Change in Balance From Baseline to 4 Weeks — 0.94; 0.76 cm
Phase 2 N=16 Novel Offloading for Diabetic Foot Ulcers With PulseFlow: A Prospective Study
Diabetic Foot Ulcer · Offloading
Primary: Lower Extremity Perfusion Change From Baseline to 4 Weeks — 167; 75 percentage of baseline perfusion
Phase 2 N=80 Herbal Preparation Used as Adjuvant Therapy on Diabetic Ulcers
Diabetic Foot Ulcer · Amputation
Primary: Number of Participants With Limb Salvage — 37; 31 Participants
N/A N=39 Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Size of Index Wound Based on Calculations Wound Width x Length x Depth 2. Size of Index Wound Based on Calculations Wound Width x Length x Depth — 2.05; 3.33 mm^3
N/A N=91 Intensive Insulin Treatment and Ischemic Foot Ulcer
Ischemic Foot Ulcer
Primary: Ischemic Foot Ulcer — 3; 10 participants
Phase 3 N=130 Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Number of 100% Wound Closure — 55.74; 50.82 percentage of patients
N/A N=12 A Non-significant Risk Clinical Study of Therapeutic Ultrasound for Patients With Diabetic Foot Ulcers.
Diabetic Foot Ulcer · Peripheral Arterial Disease · Wound; Foot
Primary: Transcutaneous Oxygen Pressure (TcPO2) — 50.96 mmHg
Phase 4 N=82 Study of Oasis Ultra in Diabetic Foot Ulcers
Diabetic Foot Ulcer
Primary: Percentage of Wounds Closed — 54; 32 percentage of wounds closed
N/A N=24 Effects of a Exercise Program on Health Outcomes in People With Diabetic Foot Ulcers
Diabetic Foot Ulcer · Diabetes Mellitus, Type 2
Primary: Glycated Hemoglobin (HbA1c) at 12-week Session — 8.0; 7.0 percentage of HbA1c — p=.26
Phase 4 N=106 DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes
Chronic Foot Ulcers
Primary: Full Epithelialization of the Wound — 16; 8 participants — p=<0.05
Phase 2 N=20 Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.
Neuropathic Diabetic Ulcer - Foot
Primary: Number of Participants Experiencing Adverse Events — 20 Participants
Phase 3 N=236 Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers
Diabetic Foot
Primary: Number of Participants With Complete Ulcer Closure — 74; 40 Participants
N/A N=545 A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers
Neuropathic Diabetic Ulcer - Foot
Primary: Incidence of Complete Wound Closure — 79; 49 participants
N/A N=51 Ultrasound Assisted Wound Debridement (UAW) Versus Standard Wound Treatment in Complicated Diabetic Foot Ulcers (DFU)
Diabetic Foot Ulcer
Primary: Change From Baseline Neo-angiogenesis (Microvessel Density) at 6 Weeks — 2.82; 1.77 score on a scale — p=<0.01
Phase 2 N=30 Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus
Diabetic Foot Infections
Primary: Number of Participants With Treatment-related Treatment-emergent Adverse Events as Graded According to the Common Terminology Criteria for Adverse Events v4.02 (CTCAE)…
Phase 3 N=276 Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients
Diabetic Foot Ulcer
Primary: Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing — 68; 31; 23; 14 participants
Phase 2 N=20 Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot
Diabetic Neuropathic Arthropathy
Primary: SUV Max on PET/CT Scan at 12 Months — 26.1; 22.9 g/ml
N/A N=160 Retrospective Record-review Study in Patients Who Had Diabetic Foot Ulcer
Diabetic Foot Ulcer
Primary: Demographic Characteristics: Weight (Mean) — 73.7; 78.3 kg
N/A N=27 Multi-layer Insoles for a Patient-specific Approach to Shear and Pressure Reduction in Diabetes-related Foot Ulcer
Diabetic Foot Ulcer · Diabetic Foot
Primary: Plantar Foot Temperature Changes in Regions-of-interest in Response to Walking — 0.758; 0.272 Absolute change in temperature degrees
N/A N=23 Continuous Diffusion of Oxygen (CDO) Treatment for Healing of Diabetic Foot Ulcers
Foot Ulcer, Diabetic
Primary: Tissue Oxygenation as Measured by Hyperspectral Imaging — 63.58; 61.91; 76.33; 77.55 percent concentration of oxyhemoglobin
Phase 4 N=17 Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Wound Appearance — 19; 19; 16.9; 14.5 units on a scale
N/A N=132 In-Home Assessment of a Smart Foot Mat for Prevention of Diabetic Foot Ulcers
Foot Ulcer, Diabetic
Primary: Occurrence of Plantar Diabetic Foot Ulcer — 37 Participants
N/A N=31 Diabetic Foot Ulcer Study on Topical Interventions
Diabetic Foot
Primary: Number of Participants With Complete Healing of Ulcer During the Observation Period — 9; 5; 4 participants
N/A N=381 Therapeutic Stockings to Prevent Foot Ulcers
Diabetes
Primary: Number of Participants Who Developed Foot Ulcer During Study Time Frame — 76; 82 Participants
Phase 3 N=48 Beta Adrenergic Antagonist for the Healing of Chronic DFU
Chronic Diabetic Foot Ulcers · Diabetic Neuropathic Ulcers · Non Healing Wound
Primary: Percentage of Complete Wound Closure, as Assessed Over a 12 Week Period — 8; 7 Participants
N/A N=10 Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .
Diabetic Peripheral Neuropathy
Primary: Measurement of b-FGF, v-EGF MEASURED BY ELISA — 30.2; 55.4; 30.3; 428.7 pg/ml — p=0.005